[go: up one dir, main page]

PE20211916A1 - Agentes aglutinantes del psma y usos de estos - Google Patents

Agentes aglutinantes del psma y usos de estos

Info

Publication number
PE20211916A1
PE20211916A1 PE2020001894A PE2020001894A PE20211916A1 PE 20211916 A1 PE20211916 A1 PE 20211916A1 PE 2020001894 A PE2020001894 A PE 2020001894A PE 2020001894 A PE2020001894 A PE 2020001894A PE 20211916 A1 PE20211916 A1 PE 20211916A1
Authority
PE
Peru
Prior art keywords
psma
antibodies
cancer
antigen
specific
Prior art date
Application number
PE2020001894A
Other languages
English (en)
Inventor
Glenn Mark Anderson
Tammy Bush
Cardoso Rosa Maria Fernandes
Ellen Chi
Judith Ann Connor
Thai Quang Dinh
Derrick Lemon Domingo
John Michael Jones
Colleen Kane
Bethany Kay Mattson
Theresa Marie Mcdevitt
Jill Marie Mooney
Richard Stephen Tawadros
Hong Mimi Zhou
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of PE20211916A1 publication Critical patent/PE20211916A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se relaciona con anticuerpos que se unen especificamente al antigeno de la membrana especifica de prostata (PSMA o PSMA) y el grupo de diferenciacion 3 (CD3), polinucleotidos que codifican los anticuerpos o fragmentos, y metodos para preparar y usar lo anteriormente mencionado. Adicionalmente, se describen metodos para usar los anticuerpos y los fragmentos de union al antigeno proporcionados. Por ejemplo, los anticuerpos especificos para PSMA y los fragmentos de union al antigeno podrian usarse para diagnosticar o monitorear la progresion, la regresion o la estabilidad del cancer que expresa PCMA; para determinar si un paciente debe recibir o no tratamiento para cancer; o para determinar si un sujeto sufre o no de un cancer que expresa PSMA y, por lo tanto, podria ser susceptible al tratamiento con un agente terapeutico contra el cancer especifico para PSMA, tal como los anticuerpos multiespecificos (biespecificos, triespecificos, etc) contra PSMA y CD3 descritos en la presente.
PE2020001894A 2018-05-24 2019-05-21 Agentes aglutinantes del psma y usos de estos PE20211916A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862676099P 2018-05-24 2018-05-24
PCT/IB2019/054189 WO2019224718A2 (en) 2018-05-24 2019-05-21 Psma binding agents and uses thereof

Publications (1)

Publication Number Publication Date
PE20211916A1 true PE20211916A1 (es) 2021-09-28

Family

ID=67253934

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001894A PE20211916A1 (es) 2018-05-24 2019-05-21 Agentes aglutinantes del psma y usos de estos

Country Status (25)

Country Link
US (1) US11746157B2 (es)
EP (1) EP3802609A2 (es)
JP (1) JP7361727B2 (es)
KR (1) KR20210015902A (es)
CN (1) CN112513085B (es)
AR (1) AR116173A1 (es)
AU (1) AU2019274657A1 (es)
BR (1) BR112020023872A2 (es)
CA (1) CA3101272A1 (es)
CL (1) CL2020003031A1 (es)
CR (1) CR20200563A (es)
DO (1) DOP2020000216A (es)
EA (1) EA202092839A1 (es)
EC (1) ECSP20082991A (es)
IL (1) IL278888A (es)
JO (1) JOP20200303A1 (es)
MA (1) MA52777A (es)
MX (1) MX2020012598A (es)
NI (1) NI202000086A (es)
PE (1) PE20211916A1 (es)
PH (1) PH12020551997A1 (es)
SG (1) SG11202011633SA (es)
TW (1) TW202016135A (es)
UY (1) UY38244A (es)
WO (1) WO2019224718A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10738132B2 (en) 2013-01-14 2020-08-11 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
IL252467B (en) 2014-11-26 2022-06-01 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
TN2017000223A1 (en) 2014-11-26 2018-10-19 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CA3029328A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
JP7530299B2 (ja) 2018-05-24 2024-08-07 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３抗体及びその使用
EP3956022A1 (en) * 2019-04-19 2022-02-23 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti- psma/cd3 antibody
AU2020259405A1 (en) * 2019-04-19 2021-09-23 Janssen Biotech, Inc. Methods of treating renal cancer with an anti- PSMA/CD3 antibody
PH12021552791A1 (en) 2019-05-10 2022-09-05 Janssen Biotech Inc Macrocyclic chelators and methods of use thereof
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US12227593B2 (en) 2020-05-20 2025-02-18 Janssen Biotech, Inc. Site-specific conjugation of glycosylated monoclonal antibodies with transglutaminase
JP7787101B2 (ja) 2020-05-20 2025-12-16 ヤンセン バイオテツク，インコーポレーテツド グリコシル化Ｆｃドメインを含むタンパク質の部位特異的コンジュゲーションのための方法
US12460001B2 (en) 2020-05-27 2025-11-04 Janssen Biotech, Inc. Proteins comprising CD3 antigen binding domains and uses thereof
JP2023532807A (ja) 2020-07-08 2023-07-31 ラヴァ・セラピューティクス・エヌ・ヴイ Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体
KR20230166150A (ko) 2020-08-19 2023-12-06 젠코어 인코포레이티드 항-cd28 조성물
US20230310599A1 (en) * 2020-09-02 2023-10-05 Genmab A/S Antibody therapy
WO2022060901A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
UY39510A (es) 2020-11-10 2022-05-31 Janssen Biotech Inc Compuestos macrocíclicos y métodos para usarlos
JP2024506831A (ja) 2021-01-28 2024-02-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイトカイン放出症候群を治療するための組成物及び方法
KR20230137393A (ko) * 2021-01-28 2023-10-04 얀센 바이오테크 인코포레이티드 Psma 결합 단백질 및 이의 용도
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
US20240209115A1 (en) 2021-04-29 2024-06-27 Amgen Inc. Methods for reducing low molecular weight species of recombinantly-produced proteins
US20230073821A1 (en) * 2021-08-27 2023-03-09 International Business Machines Corporation Antigen-binding proteins targeting coronavirus (cov) variants
WO2023084397A1 (en) 2021-11-09 2023-05-19 Janssen Biotech, Inc. Macrocyclic compounds and diagnostic uses thereof
EP4430040A1 (en) 2021-11-09 2024-09-18 Janssen Biotech, Inc. Macrocyclic compounds and methods of making the same
WO2023152581A1 (en) * 2022-02-09 2023-08-17 Janssen Biotech, Inc. Method of treating cancer with psmaxcd3 antibody
CA3252619A1 (en) 2022-02-23 2023-08-31 Xencor, Inc. Anti-CD28 and anti-PSMA antibodies
JP2025509892A (ja) 2022-03-21 2025-04-11 アムジェン インコーポレイテッド 前立腺癌の治療のためのｔ細胞エンゲージ分子を用いた併用療法
CN118922449A (zh) * 2022-04-11 2024-11-08 江苏恒瑞医药股份有限公司 特异性结合psma和cd28的抗原结合分子及其医药用途
CN120456931A (zh) * 2022-12-22 2025-08-08 詹森药业有限公司 制备抗体-多核苷酸缀合物的方法
KR20250158048A (ko) 2023-03-03 2025-11-05 아스널 바이오사이언시스, 인크. Psma 및 ca9을 표적으로 하는 시스템
WO2025096433A1 (en) * 2023-10-30 2025-05-08 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (psma) and uses thereof

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US541606A (en) 1895-06-25 Sealed package
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
DE69233803D1 (de) 1992-10-28 2011-03-31 Genentech Inc Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ATE501170T1 (de) 1997-04-07 2011-03-15 Genentech Inc Verfahren zur herstellung humanisierter antikörper durch randomisierte mutagenese
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
NZ500078A (en) 1997-04-07 2001-10-26 Genentech Inc Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
ATE294860T1 (de) 1997-09-16 2005-05-15 Egea Biosciences Llc Methoden zur kompletten chemischen synthese und zusammensetzung von genen und genomen
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
DK1242438T3 (da) 1999-12-29 2007-02-12 Immunogen Inc Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1916303B1 (en) 2000-11-30 2013-02-27 Medarex, Inc. Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
EP2407473A3 (en) 2002-02-01 2012-03-21 ARIAD Pharmaceuticals, Inc Method for producing phosphorus-containing compounds
SI2275102T1 (sl) 2002-03-13 2015-12-31 Array Biopharma, Inc. N3 alkilirani benzimidazol derivati kot MEK inhibitorji
US20050186208A1 (en) 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
AU2004242845B2 (en) 2003-05-31 2011-06-02 Amgen Research (Munich) Gmbh Human-anti-human CD3 binding molecules
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
PT2489364E (pt) 2003-11-06 2015-04-16 Seattle Genetics Inc Compostos de monometilvalina conjugados com anticorpos
EP2397189B1 (en) 2003-11-14 2015-03-18 Brigham and Women's Hospital, Inc. Methods of modulating immunity
RS55551B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
SI1761528T1 (sl) 2004-06-11 2008-06-30 Japan Tobacco Inc 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
MX2007002856A (es) 2004-09-02 2007-09-25 Genentech Inc Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007004415A1 (ja) 2005-07-01 2007-01-11 Murata Manufacturing Co., Ltd. 多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
JP5448818B2 (ja) 2006-08-21 2014-03-19 ジェネンテック， インコーポレイテッド アザベンゾフラニル化合物および使用方法
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
CL2008003810A1 (es) 2007-12-19 2009-05-22 Genentech Inc Compuestos derivados de 5-anilino imidazol[1,5-a]piridina o pirazina, inhibidores de la actividad mek quinasa; composiciones farmaceuticas que los contienen; y su uso para tratar trastornos hiperproliferativos y una enfermedad inflamatoria.
CA2710373A1 (en) 2007-12-19 2009-07-09 Ping Tsui Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
WO2010006086A2 (en) 2008-07-08 2010-01-14 Intellikine, Inc. Kinase inhibitors and methods of use
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
CA2738565C (en) 2008-10-01 2023-10-10 Micromet Ag Cross-species-specific psmaxcd3 bispecific single chain antibody
WO2010045340A1 (en) 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Methods of humanizing and affinity-maturing antibodies
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PE20120540A1 (es) 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
ES2989108T3 (es) 2010-04-20 2024-11-25 Genmab As Proteínas que contienen FC de anticuerpos heterodiméricos y métodos para producir las mismas
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
KR20190133790A (ko) 2011-08-01 2019-12-03 제넨테크, 인크. Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
AU2012332021B8 (en) 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
EP2855531A1 (en) 2012-05-24 2015-04-08 F. Hoffmann-La Roche AG Multispecific antibodies
KR20250054125A (ko) 2012-11-21 2025-04-22 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
EP3192812B1 (en) 2013-12-17 2020-05-27 Genentech, Inc. Anti-cd3 antibodies and methods of use
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
AP2016009586A0 (en) 2014-05-29 2016-11-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
EP3722315A1 (en) 2014-09-05 2020-10-14 Janssen Pharmaceutica NV Cd123 binding agents and uses thereof
BR112017023829A2 (pt) * 2015-05-06 2018-07-31 Janssen Biotech Inc agentes de ligação biespecíficos de antígeno de membrana específico da próstata (psma) e usos dos mesmos
HK1253005A1 (zh) * 2015-05-06 2019-06-06 Janssen Biotech, Inc. 前列腺特异性膜抗原结合iii型纤连蛋白结构域
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
MA43959A (fr) 2016-02-03 2018-12-12 Amgen Res Munich Gmbh Constructions d'anticorps impliquant des cellules t bispécifiques psma et cd3
WO2018042071A1 (en) 2016-08-30 2018-03-08 Nokia Technologies Oy Controlling transmission of information on radio links used in aggregation
AU2018388467B2 (en) 2017-12-18 2025-01-09 Janssen Biotech, Inc. Radiolabeling of polypeptides
JP7395508B2 (ja) * 2018-05-16 2023-12-11 ヤンセン バイオテツク，インコーポレーテツド 癌を治療する方法及びｔ細胞リダイレクト治療薬の有効性を向上させる方法
JP7530299B2 (ja) 2018-05-24 2024-08-07 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３抗体及びその使用

Also Published As

Publication number Publication date
MX2020012598A (es) 2021-05-27
CN112513085B (zh) 2024-06-18
CN112513085A (zh) 2021-03-16
EA202092839A1 (ru) 2021-02-12
BR112020023872A2 (pt) 2021-02-17
UY38244A (es) 2019-11-29
CL2020003031A1 (es) 2021-04-16
AR116173A1 (es) 2021-04-07
WO2019224718A2 (en) 2019-11-28
EP3802609A2 (en) 2021-04-14
US11746157B2 (en) 2023-09-05
KR20210015902A (ko) 2021-02-10
CA3101272A1 (en) 2019-11-28
US20200024360A1 (en) 2020-01-23
AU2019274657A1 (en) 2020-12-10
JOP20200303A1 (ar) 2020-11-23
TW202016135A (zh) 2020-05-01
IL278888A (en) 2021-01-31
PH12020551997A1 (en) 2021-09-06
ECSP20082991A (es) 2021-01-29
DOP2020000216A (es) 2021-09-15
WO2019224718A3 (en) 2020-03-05
JP7361727B2 (ja) 2023-10-16
NI202000086A (es) 2021-03-23
MA52777A (fr) 2021-04-14
SG11202011633SA (en) 2020-12-30
CR20200563A (es) 2021-05-11
JP2021524250A (ja) 2021-09-13

Similar Documents

Publication Publication Date Title
PE20211916A1 (es) Agentes aglutinantes del psma y usos de estos
AR134557A2 (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estas
AR133826A2 (es) Anticuerpos anti-gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas
NI201700025A (es) Agentes de unión a cd123 y usos de estos.
ECSP18040535A (es) Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
BR112017001513A2 (pt) molécula de ligação biespecífica, polinucleotídeo, vetor, célula ex vivo, método de produção de uma molécula de ligação biespecífica, mistura de polinucleotídeos, composição farmacêutica, método de tratamento de um câncer, método de preparação de uma célula
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CO2020001981A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
EA202092861A1 (ru) Специфичные в отношении злокачественной опухоли t-клеточные рецепторы
MX2021012869A (es) Anticuerpo anti-tie2 y uso del mismo.
CO2019001967A2 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1